PBC Ireland

Romeo M, et al. 2025. The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives. J Pers Med (Dec 2025)

Wang Z, et al. 2025. Vitamin D attenuates hepatic inflammation in primary biliary cholangitis by inhibiting TLR4/NF-κB mediated M1 macrophage polarization. Sci Rep (Dec 2025)

Chen Z, et al. 2025. The causal relationship between inflammatory bowel disease and primary biliary cholangitis: A bidirectional two-sample Mendelian randomization study. Medicine (Baltimore) (Dec 2025)

Li Y, et al. 2025. Systemic inflammatory response index: a novel predictor for cardiovascular disease risk in patients with primary biliary cholangitis. Eur J Med Res (Dec 2025)

Wang W, et al. 2025. Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia. Front Immunol (2025)

Böttcher MH, et al. 2025. Association between quality of life and inflammation and fibrosis markers in primary biliary cholangitis over three-year follow-up. Scand J Gastroenterol (Dec 2025)

Invernizzi P, et al. 2025. Primary biliary cholangitis (PBC): evolving approaches and expert perspectives. Expert Rev Gastroenterol Hepatol (Dec 2025)

Yang P, et al. 2025. Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome with primary biliary cholangitis and alcoholic liver disease: a case report. Front Med (Lausanne) (2025)

Jin M. 2025. Comment on "Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan". J Formos Med Assoc (Dec 2025)

Chen PT, Chen HW. 2025. Reply to "Comment on 'Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan'". J Formos Med Assoc (Dec 2025)

Dar MS, et al. 2025. Randomized Controlled Trial Evidence on Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Int J Hepatol (2025)

Mimura S, et al. 2025. Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets. J Clin Med (Nov 2025)

Mandea M, et al. 2025. From Isolation to Information: Launching an Online Community for Patients with Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, and Autoimmune Hepatitis in Romania-A Descriptive Study. Healthcare (Basel) (Dec 2025)

Luo PY, et al. 2025. Autophagy of Kupffer cells modulates CD8 T cell activation in primary biliary cholangitis. Gut (Dec 2025)

Stein K, et al. 2025. Clinical characteristics of newly diagnosed patients with primary biliary cholangitis (PBC) indicate the need for better awareness on timely diagnosis and adequate UDCA therapy. Z Gastroenterol (Dec 2025)

Gish RG, et al. 2025. Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United States. J Med Econ (Dec 2025)

van Hooff MC, et al. 2025. Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study. Am J Gastroenterol (Dec 2025)

Han J, Xu Q. 2025. Diagnostic Pitfalls in Primary Biliary Cholangitis: Delta Bilirubin and Lipoprotein-X Interferences. Clin Lab (Dec 2025)

Jin Y, et al. 2025. Quantitative detection of anti-centromere antibodies in primary biliary cholangitis: value of chemiluminescence immunoassay. Scand J Clin Lab Invest (2025)

Koriem KMM. 2025. Tumor necrosis factor alpha-induced protein 3: Biomarker discovery and therapeutic advancement in primary biliary cholangitis. World J Hepatol (Nov 2025)

Liu Z, et al. 2025. Bile Acid Metabolites Control Th17/Treg Balance in Primary Biliary Cholangitis: Mechanisms of Disease Progression and Therapeutic Targets. J Gastroenterol Hepatol (Dec 2025)

Kumar S, et al. 2025. Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States. Adv Ther (Dec 2025)

Vierling JM, et al. 2025. Fracture events in patients with primary biliary cholangitis during treatment with seladelpar in the phase III RESPONSE trial. Hepatol Commun (Dec 2025)

Haque T, et al. 2025. AMA-Negative Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome Presenting With Bullous Pemphigoid: A Case Report. Clin Case Rep (Dec 2025)

Rogalska M, et al. 2025. Altered sphingolipid profile in primary biliary cholangitis: associations with fibrosis and inflammation. Sci Rep (Nov 2025)

Mandea M, et al. 2025. Profile of Patients with Primary Biliary Cholangitis and Evaluation of Response to Ursodeoxycholic Acid in a Romanian Center-Retrospective Study. J Clin Med (Nov 2025)

Ma X, et al. 2025. Proteomics identifies complement protein signatures in patients with primary biliary cholangitis. Eur J Med Res (Nov 2025)

Choi G, et al. 2025. Optimizing Care in Primary Biliary Cholangitis: Current Treatments and the Second-Line Decision. Dig Dis Sci (Nov 2025)

Chen JL, et al. 2025. Real-world performance of transient elastography in assessing advanced fibrosis in Chinese patients with primary biliary cholangitis. World J Gastroenterol (Nov 2025)

Angelara M, et al. 2025. Primary biliary cholangitis. Treatment options in 2025. A narrative review. Front Immunol (2025)

Bersuch LA, De Gottardi A. 2025. Exploring Maralixibat for Treatment-Resistant Pruritus in Intrahepatic Cholestasis of Pregnancy and Primary Biliary Cholangitis: A Case Report. Am J Case Rep (Nov 2025)

Ritter TE, et al. 2025. Association of liver biomarker values beyond current thresholds and negative clinical outcomes in primary biliary cholangitis: analysis of a real-world healthcare claims database. J Comp Eff Res (Dec 2025)

Lantinga MA. 2025. What the European Reference Network Registry for Rare Liver Diseases Tells Us About Primary Biliary Cholangitis in European Practice. United European Gastroenterol J (Dec 2025)

Zhang Y, et al. 2025. HSC-derived exosomal miR-122-5p inhibits EMT and fibrosis of intrahepatic biliary epithelial cells to alleviate primary biliary cholangitis. Front Immunol (2025)

Bantel H, et al. 2025. Optimizing clinic consultations in primary biliary cholangitis: International consensus recommendations. Hepatol Commun (Dec 2025)

Popescu I. 2025. PPARevolution. First PPARδ Agonist and a Dual PPARα/PPARδ Activator Approved for the Treatment of Primary Biliary Cholangitis. J Cell Mol Med (Nov 2025)

Pei Y, et al. 2025. Letter on 'Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis'. Aliment Pharmacol Ther (Nov 2025)

Tang X, You X. 2025. Progress and prospects of gut microbiota-targeted therapy for primary biliary cholangitis. Gut Pathog (Nov 2025)

Tana MM, Hirschfield GM. 2025. Primary Biliary Cholangitis. JAMA (Nov 2025)

Lakshmanan V, Morris L. 2025. Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary Cholangitis. Cureus (Oct 2025)

Zhou AE, et al. 2025. Treatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib. J Drugs Dermatol (Nov 2025)

Liu C, et al. 2025. Letter: Optimizing Risk Stratification in Primary Biliary Cholangitis-The Role of Biochemical Response as a Dynamic Predictor. Aliment Pharmacol Ther (Nov 2025)

Hirschfield GM, et al. 2026. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol (Jan 2026)

Lohse AW, Assis DN. 2026. Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis. Lancet Gastroenterol Hepatol (Jan 2026)

Kowdley KV, et al. 2025. Treatment Persistence, Normal Alkaline Phosphatase and Clinical Outcomes in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Oct 2025)

Kuo SZ, et al. 2025. Research Communication: Real-World Clinical Experience With Seladelpar in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Oct 2025)

Jamal F, et al. 2025. Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. Biomedicines (Sep 2025)

Ye X, et al. 2025. Noninvasive elastography-based assessment of liver fibrosis in primary biliary cholangitis. Ann Hepatol (Oct 2025)

Zhang M, et al. 2025. The Genomics/Genetics of Primary Biliary Cholangitis: The Case for a Functional SNP rs10893900 in ETS1/FLI1 and Review of the Literature. Clin Rev Allergy Immunol (Oct 2025)

Li J, et al. 2025. Autophagy Sustained the Activation and Survival of Liver-infiltrating CD8 T Cells in Primary Biliary Cholangitis. Immunol Invest (Oct 2025)

Tao Y, et al. 2025. The role of mitochondria-related key genes in primary biliary cholangitis was analyzed based on transcriptome sequencing data. Front Immunol (2025)

Ren W, et al. 2025. Identification of galangin as a therapeutic candidate for primary biliary cholangitis via systematic druggable genome-wide Mendelian randomization analysis and experimental validation. Front Pharmacol (2025)

Passos PRC, et al. 2025. Recurrent primary biliary cholangitis after liver transplantation: A global meta-analysis of epidemiology and risk factors. Am J Transplant (Oct 2025)

Harada K, et al. 2025. Histological characteristics of primary biliary cholangitis in patients with incomplete responses to ursodeoxycholic acid. Hum Pathol (Dec 2025)

Gordon SC, et al. 2025. Assessment of adherence to guidelines for biochemical monitoring and ursodeoxycholic acid treatment response in a retrospective cohort of US patients with primary biliary cholangitis. BMJ Open Gastroenterol (Oct 2025)

Gerussi A, et al. 2025. Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER). United European Gastroenterol J (Dec 2025)

Forero Vásquez BN, et al. 2025. Mixed Multiple Autoimmune Syndrome Type 3 With Coexistence of Primary Biliary Cholangitis, Inflammatory Myopathy, and Chronic Thyroiditis: A Case Report. Cureus (Sep 2025)

Curto A, et al. 2025. Advancing the management of primary biliary cholangitis: From pathogenesis to emerging therapies. World J Clin Cases (Oct 2025)

Chen R, et al. 2025. Innate immunity of bile and cholangiocytes in primary biliary cholangitis. Front Immunol (2025)

Das TS, Vuppalanchi R. 2025. Recent Advances in Primary Biliary Cholangitis Treatment. Clin Liver Dis (Nov 2025)

Shen G, et al. 2025. The effects of lifestyle factors on primary biliary cholangitis ascertained by two-sample Mendelian randomization. Am J Med Sci (Oct 2025)

Yu C, et al. 2025. Impact of the prognostic nutritional index on the recompensation of patients with decompensated primary biliary cholangitis. Front Immunol (2025)

. 2025. Correction to 'Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study'. Liver Int (Nov 2025)

Ye K, et al. 2025. Common pathological mechanisms and therapeutic strategies in primary Sjogren's syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy. Front Immunol (2025)

Herta T, et al. 2025. Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care. Ann Hepatol (Oct 2025)

Koc OM, et al. 2026. Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases. Lancet Gastroenterol Hepatol (Jan 2026)

Floreani A, et al. 2025. An update on novel investigational agents for the treatment of primary biliary cholangitis. Expert Opin Investig Drugs (Oct 2025)

Zhang J, Hirata Y. 2025. Response to "Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others?". Hepatol Res (Oct 2025)

Corpechot C, et al. 2025. Bezafibrate for primary biliary cholangitis: time to act on the evidence. Nat Rev Gastroenterol Hepatol (Dec 2025)

Arase Y, et al. 2025. Denosumab versus zoledronic acid for osteoporosis treatment in patients with primary biliary cholangitis (the DELTA Study): A multicenter, non-inferiority randomized trial. Hepatol Commun (Nov 2025)

Luo H, et al. 2025. Causal association between dietary factors and Primary Biliary Cholangitis: A Mendelian randomization study. Medicine (Baltimore) (Oct 2025)

Martins A, et al. 2025. Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis. Hepatology (Jul 2025)

Wong YJ, et al. 2025. Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis. J Hepatol (Oct 2025)

Ma H, et al. 2026. Profiling of circulating T follicular helper and T peripheral helper cell subsets in patients with primary biliary cholangitis. Immunol Lett (Feb 2026)

Zhang X, et al. 2025. The Depletion of Plasma Cells but Not CD20B Cells Alleviates Primary Biliary Cholangitis. Liver Int (Nov 2025)

Du Q, et al. 2025. Absence of bidirectional causality between primary biliary cholangitis and major depression: A two-sample Mendelian randomization study. Medicine (Baltimore) (Sep 2025)

Abreu ES, et al. 2025. Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis. J Gastroenterol Hepatol (Dec 2025)

Bhatnagar P, Eid N. 2025. Rapamycin nanoparticles suppress autoreactive lymphocytes and reduce anti-mitochondrial antibodies in primary biliary cholangitis: Mechanisms and implications. World J Hepatol (Sep 2025)

Liu HL, et al. 2025. Comparison of pathological features of patients with antibody-negative and positive primary biliary cholangitis. BMC Gastroenterol (Sep 2025)

Cançado GGL, et al. 2025. High biochemical remission rates in patients with primary biliary cholangitis treated with "triple" anticholestatic therapy. Hepatol Commun (Oct 2025)

Zhang Z, Yang Z. 2025. Which Cells Play a Protective Role in Primary Biliary Cholangitis: Dendritic Cells or Others? Hepatol Res (Sep 2025)

Abbas N, et al. 2025. Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Sep 2025)

Sirohi N, et al. 2025. Dismal Prognosis of Primary Biliary Cholangitis and Its Overlap with Autoimmune Hepatitis. J Clin Exp Hepatol (2025)

Nie Y, et al. 2025. Gut Microbiota: Implications in Pathogenesis and Potential Therapeutic Target in Primary Biliary Cholangitis. J Clin Transl Hepatol (Sep 2025)

Zhang W, et al. 2025. A Bibliometric Analysis of Immunological Research in Primary Biliary Cholangitis: Global Patterns and Emerging Directions. Cureus (Aug 2025)

Zhang M, et al. 2025. Genetic architecture of primary biliary cholangitis: strong evidence for HLA and non-HLA risk loci. Front Immunol (2025)

Kugiyama Y, et al. 2025. Clinical Characteristics and Long-Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd-Generation Nationwide Survey. Hepatol Res (Sep 2025)

Brice C, Louvet A. 2025. [New therapeutic approaches for the treatment of primary biliary cholangitis]. Med Sci (Paris) (2025)

Liao W, et al. 2025. Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis. Therap Adv Gastroenterol (2025)

Memon A, et al. 2025. A comprehensive review of systemic sclerosis-primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype. Curr Opin Rheumatol (Nov 2025)

Wang X, et al. 2025. Clinical characteristics of dyslipidemia in patients with primary biliary cholangitis: a single-center experience in China. Clin Rheumatol (Oct 2025)

Herta T, Berg T. 2025. [Primary biliary cholangitis-Update on diagnostics, risk stratification and new treatment options]. Inn Med (Heidelb) (Sep 2025)

Pan SD, et al. 2025. MicroRNA-126-3p as a predictive biomarker for patients with primary biliary cholangitis refractory to ursodeoxycholic acid. World J Gastroenterol (Aug 2025)

Han HQ, et al. 2025. Peripheral basophil activation: A hidden player in the immunopathogenesis of primary biliary cholangitis. World J Hepatol (Aug 2025)

Abuelazm M, et al. 2025. The Efficacy and Safety of Seladelpar for Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. JGH Open (Sep 2025)

Del Barrio M, et al. 2025. Primary Biliary Cholangitis: Immunopathogenesis and the Role of Bile Acid Metabolism in Disease Progression. Int J Mol Sci (Aug 2025)

Buck L, et al. 2025. An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis. Sci Rep (Aug 2025)

Ding D, et al. 2025. Definition and validation of recompensation in patients with primary biliary cholangitis-related decompensated cirrhosis treated with ursodeoxycholic acid: Based on the BAVENO VII criteria. J Transl Int Med (Aug 2025)

Lu W, et al. 2026. Fibroblast growth factor 19 in combination with liver fibrosis markers for non-invasive diagnosis of primary biliary cholangitis-associated cirrhosis. Clin Chim Acta (Jan 2026)

Abid S, et al. 2025. Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape. Ann Med Surg (Lond) (Jul 2025)

(Facebook is for Irish PBC patients only)

Recent News

URSO Calculator

Jul 27th, 2025
The PBC Ireland Patient Registry is now LIVE!

Jul 26th, 2025
PBC Ireland will attend Global Liver Institute's A3 Program in Washington, DC

May 8th, 2025
PBC Ireland Launched!

Publications(100 publications from PubMed)

Recent News

Publications
(100 publications from PubMed)